|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM318753677 |
| 003 |
DE-627 |
| 005 |
20250228131823.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108647
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1062.xml
|
| 035 |
|
|
|a (DE-627)NLM318753677
|
| 035 |
|
|
|a (NLM)33310069
|
| 035 |
|
|
|a (PII)S1521-6616(20)30807-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a McCann, Liza J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Is it time to re-think juvenile-onset Rheumatic and Musculoskeletal Diseases? - First steps towards individualised treatments to meet agreed targets
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.06.2021
|
| 500 |
|
|
|a Date Revised 14.06.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Editorial
|
| 650 |
|
4 |
|a Biomarkers
|
| 650 |
|
4 |
|a Child
|
| 650 |
|
4 |
|a Classification
|
| 650 |
|
4 |
|a Inflammation
|
| 650 |
|
4 |
|a Paediatric rheumatology
|
| 650 |
|
4 |
|a Stratified
|
| 650 |
|
4 |
|a Treatment
|
| 650 |
|
7 |
|a Antirheumatic Agents
|2 NLM
|
| 700 |
1 |
|
|a Hedrich, Christian M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 223(2021) vom: 19. Feb., Seite 108647
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:223
|g year:2021
|g day:19
|g month:02
|g pages:108647
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108647
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 223
|j 2021
|b 19
|c 02
|h 108647
|